Erratum: Expression of Concern: A Rational Diagnostic Algorithm for the Identification of ALK Rearrangement in Lung Cancer: A Comprehensive Study of Surgically Treated Japanese Patients (PLoS ONE (2013) 8:8 (e69794) DOI: 10.1371/journal.pone.0069794);A Rational Diagnostic Algorithm for the Identification of ALK Rearrangement in Lung Cancer: A Comprehensive Study of Surgically Treated Japanese Patients

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Takamochi, Kazuya ^a   Takeuchi, Kengo ^b   Hayashi, Takuo ^a   Oh, Shiaki ^a   Suzuki, Kenji ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; AGED; ALK GENE; ARTICLE; CANCER STAGING; DIAGNOSTIC ACCURACY; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MUTATOR GENE; ONCOGENE K RAS; PRIMARY TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE; TUMOR VOLUME;

ADULT; ALGORITHMS; ASIAN CONTINENTAL ANCESTRY GROUP; DNA MUTATIONAL ANALYSIS; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; RECEPTOR PROTEIN-TYROSINE KINASES; SENSITIVITY AND SPECIFICITY;

EID: 84881011927     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0278808     Document Type: Erratum

References (29)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
3. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
5. Shigematsu H, Gazdar AF, (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262.
6. Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, et al. (2009) Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 40: 1152-1158.
7. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, et al. (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22: 508-515.
8. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283.
9. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, et al. (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 6: 466-472.
10. Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, et al. (2008) EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 10: 298-302.
11. Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, et al. (2008) EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61: 163-169.
12. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, et al. (2009) Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4-ALK Fusion Gene. Ann Surg Oncol.
13. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, et al. (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723-1733.
14. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, et al. (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15: 5216-5223.
15. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, et al. (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14: 6618-6624.
16. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, et al. (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143-3149.
17. Nagai Y, Miyazawa H, Huqun T, Udagawa K, (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282.
18. Thiede C, Bayerdorffer E, Blasczyk R, Wittig B, Neubauer A, (1996) Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res 24: 983-984.
19. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247-4253.
20. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ, (2012) Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 136: 796-803.
21. Takeuchi K, (2013) Interpretation of Anti-ALK Immunohistochemistry Results. J Thorac Oncol 8: e67-68.
22. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, et al. (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 14: 590-598.
23. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43.
24. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, et al. (2012) A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res 18: 5682-5689.
25. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
26. Wong DW, Leung EL, Wong SK, Tin VP, Sihoe AD, et al. (2011) A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 117: 2709-2718.
27. Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, et al. (2012) KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 7: e31323.
28. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, et al. (2012) Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 76: 403-409.
29. Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, et al. (2010) EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res 16: 4938-4945.